Allergan Aesthetics today announced its plans to roll out Skinvive in 35 additional markets this year.
Skinvive is the first and only FDA-approved hyaluronic acid injectable treatment in the U.S. to improve skin smoothness of the cheeks, according to the company.
“This extensive rollout marks an exciting new era for Allergan Aesthetics, placing a greater emphasis on skin quality,” Mark Wilson, senior vice president of international commercial, said in a statement.
With the expansion, the company will have launched Skinvive in 57 markets worldwide.
Allergan is the Irvine-based aesthetics unit of biopharmaceutical giant AbbVie Inc.
